Spectral AI Inc (MDAI) Q4 2024 Earnings Call Highlights: Record R&D Revenue and Strategic ...

Live

Stocks are rallying as Trump eased fears over China tariffs and Powell. See the latest.

GuruFocus News

Fri, Mar 28, 2025, 1:04 AM 4 min read

Research and Development Revenue (Q4 2024): $7.6 million, up from $5.3 million in the prior year period.
Gross Margin (Q4 2024): 44%, down from 46.1% in the prior year period.
General and Administrative Expenses (Q4 2024): $4.6 million, down from $5.4 million in the prior year period.
Research and Development Revenue (Full Year 2024): $29.6 million, a 63.5% increase from $18.1 million in 2023.
Gross Margin (Full Year 2024): 44.9%, up from 43.6% in 2023.
General and Administrative Expenses (Full Year 2024): $19.9 million, down from $20.9 million in 2023.
R&D Expenses (Full Year 2024): $19.3 million, up from $15.1 million in 2023.
Cash and Cash Equivalents (End of 2024): $5.2 million.
Current Cash Position: Exceeds $14 million following long-term debt financing.
Forecasted Revenue (Fiscal Year 2025): Approximately $21.5 million.

Warning! GuruFocus has detected 2 Warning Signs with MDAI.

Release Date: March 27, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Spectral AI Inc (NASDAQ:MDAI) achieved positive topline results in their burn validation study, demonstrating the exceptional performance of their DeepView system in predicting burn healing potential.
The company successfully deployed DeepView systems in Australia, expanding their presence and gathering valuable real-world clinical data.
Spectral AI Inc (NASDAQ:MDAI) reported a 63.5% increase in research and development revenue for 2024, marking the highest revenue in the company's history.
The development of the Snapshot M, a portable diagnostic tool, has been heavily supported by government funding, with total awards exceeding $7 million.
Spectral AI Inc (NASDAQ:MDAI) has formed Spectral IP, a dedicated intellectual property subsidiary, to monetize IP assets within the healthcare and AI-driven technology sectors.

Negative Points

Gross margin in the fourth quarter declined to 44% from 46.1% in the prior year period.
The company anticipates a step back in revenue for 2025 as they position for FDA submission and cannot roll out in the US until de novo clearance is obtained.
General and administrative expenses in 2024 were $19.9 million, reflecting a decrease from 2023 but still a significant expenditure.
Spectral AI Inc (NASDAQ:MDAI) faces challenges in commercial readiness, including the need to mobilize a sales force and gather real-world evidence to support commercialization.
The spinoff of Spectral IP into an independent publicly traded company is subject to final board and regulatory approvals, with no assurance regarding the ultimate timing or completion of this transaction.

Q & A Highlights

Q: What are Spectral AI's plans for commercialization and staffing as they approach the launch of their product? A: Dr. J. Michael Dimaio, Non-Executive Director, explained that they are preparing for FDA clearance and will precondition the market through studies, presentations, and publications. They are mobilizing a sales force and gathering real-world evidence from the UK and Australia to support commercialization. However, specific details on staffing and co-promotion partners are still under discussion.

Q: How does Spectral AI plan to manage sales and medical liaisons if they pursue a go-alone strategy? A: Dr. J. Michael Dimaio stated that they already have service personnel for research purposes and are planning to roll out approximately 170 more units under a federal government contract. A small sales force will be necessary for the initial rollout, but the exact number of sales reps and medical specialists needed is not yet determined.

Q: Can you explain the expected revenue for 2025 and the potential for commercial revenue? A: Vincent Capone, CFO, noted that 2025 is expected to see a step back in revenue as they prepare for FDA submission and clearance. The forecasted revenue of $21.5 million does not include potential commercial revenue from the UK or Australia, as these are not expected to significantly impact overall revenue.

Q: What are the remaining steps for FDA submission following the positive results of the validation study? A: Dr. J. Michael Dimaio outlined that they need to complete the statistical plan, hardware and software validation, and other sections required for the FDA application. The submission will be reviewed by BARDA before going to the FDA.

Q: Can you provide more context on the dice score and its importance in the FDA's evaluation? A: Dr. Jihong Wang, Director of Data Science, explained that the dice score measures the overlap between AI model segmentation and ground truth, providing a balanced view of the model's performance. The FDA requires both detection and segmentation performance metrics to understand the device's capabilities.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

Terms and Privacy Policy

Your Privacy Choices

Utah Privacy Notice

More Info